⌕
Altimmune · ALT · Nasdaq
Tenet 54 · Mixed
Compare
$1.56−5.17%At closeTenet 54 · Mixed
$1.56−0.09 (−5.17%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Altimmune (ALT) Earnings Forecast

What Wall Street expects this business to earn, and how much analysts disagree.

Sources Analyst estimates EstimatesConsensus as of How we compute thisNot investment advice
Estimates are in the company's reporting currency and are not compared to the USD share price on this page. Estimates are reported in the company's local reporting currency and are not comparable to the USD share price, so the forward P/E and per-row implied multiples are hidden.
Consensus as of Nov 16, 2026 · we check it nightly

Analysts expect Altimmune to lose 0.61 a share in FY26 and 0.73 in FY30. 5 analysts publish an estimate for FY26 and 5 for FY30.

Forward P/E · FY26E
Not shown
the estimate and the price are in different currencies
FY26 EPS revisions · 30 days
▼ −5.0%
−0.58 to −0.61, one fiscal year at both ends
Disagreement · FY26
0.13
wide, −0.68 to −0.56
Coverage · FY26
5 · 6
EPS estimates · revenue estimates
Work out what the consensus implies at a multiple you chooseConsensus estimates only. Analysts' price forecasts and ratings are not licensed here.

Are estimates going up or down lately?

The FY26 EPS consensus is −0.61, a loss that widened 5.0% in 90 days, on the 39 days of it our record holds. Every figure compares one fiscal period at both ends.

EPS consensus, change over the last 90 days. One step per nightly change.

−6.9%−2.9%+1.0%FY26 −5.0%FY27 −5.8%Oct 8Nov 16
EPS30 days90 daysshown above
FY265 analysts▼ −5.0%−0.58 to −0.6139 of 90 days−5.0% so far
FY277 analysts▼ −5.8%−0.64 to −0.6739 of 90 days−5.8% so far
Dec '264 analysts▼ −9.1%−0.16 to −0.1739 of 90 days−9.1% so far
Mar '273 analysts1 of 30 days0.0% so far1 of 90 days0.0% so far

Contributors at both ends of the window: FY26 7 and 5. A change in the average can come from a new contributor as much as from a changed mind, so both counts stay in view.

Measured between two of our own nightly snapshots of one fiscal period, so a new fiscal year entering the view is never read as a revision. Never backfilled. A window still filling says how many days it holds; a blank one means our record is not that long yet.

If the Street is right, what does that imply for the share price?

Price at last close · consensus as of Nov 16, 2026

The near-year consensus is −0.61 a share in the company's reporting currency, and a ratio carries no currency, so a multiple can still be chosen. We stop before the product: it would be a price in the reporting currency, and this share trades in US dollars.

Consensus EBITDA · FY26
−0.1B
5 analysts · low −0.1B, high −0.0B · thin coverage
Multiple · EV/EBITDA · yours
No year of positive EBITDA or earnings on record to take a default from, so the multiple can only be yours.
Receipt · ALT · FY26Nov 16, 2026
Implied, a share
Not computed

We do not convert currencies here. The estimate is in the reporting currency and the share trades in US dollars, so the product would be a price in neither.

This is multiplication, not a forecast. It assumes the market pays the multiple you chose and that the consensus is right. Both are often wrong.

Not computed across currencies. The consensus is in Altimmune's reporting currency and the share trades in US dollars, so there is no multiple of this year's estimate to set against a growth rate.

How much do analysts disagree?

For FY30, estimates run from −0.73 to −0.73 around an average of −0.73, drawn by 5 analysts.

FY26E5 analysts
−0.68 to −0.56 · 0.13 wide
FY27E7 analysts
−0.90 to −0.55 · 0.35 wide
FY28E8 analysts
−0.97 to −0.42 · 0.55 wide
FY29E5 analysts
−0.70 · only 5 estimates
FY30E5 analysts
−0.73 · only 5 estimates

A wide spread is disagreement, not risk; a narrow one is agreement, not accuracy. Later years are always wider because fewer people forecast them. Bars in amber rest on fewer than 15 analysts. The tick on each bar is the average. The last filed figure is in US dollars, so it is not placed on this axis. Spreads are shown in currency rather than as percentages, because a percentage of a number near zero overstates it.

Is next quarter a high bar or an easy one?

Analysts expect Altimmune to lose 0.17 a share in the December quarter, the average of 4 estimates. We hold no expected date for the next report. Last quarter, which ended in September, Altimmune lost 0.15 a share. Analysts had expected a loss of 0.13, so the loss came in 13.2% larger.

Expected report
Not held
No expected date is published for this company's next report, so none is printed here.
Revenue expected · December quarter
1.8K
9 analysts, 1.8 to 1.8 in reporting ccy K

For the March quarter, analysts expect a loss of 0.16 a share.

Does Altimmune usually beat or miss?

So far we have checked 1 quarter: the one that ended in September 2026, when Altimmune lost 0.15 a share against the a loss of 0.13 analysts expected, 13.2% larger. We add a quarter to this record each time Altimmune reports.

We started recording estimates on Oct 8, 2026, so quarters that reported before that date cannot be checked.

Before our record
Sep '25
Mar '26
Jun '26
Our record, one quarter per report
−13.2%
Sep '26reaction
−16.6%
Dec '26not reported yet
Mar '27
Jun '27
Sep '27
Dec '27
Mar '28
Jun '28
Sep '28
Dec '28
Mar '29
Jun '29
Checked so far
1 quarter
one more every report
Beat expectations
0 of 1
full details on the Earnings tab
Share price reaction
−16.6%
one session, timed to the September 2026 release
Typical gap vs estimate
Not yet
shown once 4 quarters are checked

Checked against the company's reported figure (GAAP) and the average estimate we recorded the night before its results release. Where analysts' number is on an adjusted basis, we leave the comparison out rather than force it. We started recording estimates for Altimmune on Oct 8, 2026, so earlier quarters cannot be checked, and we never fill them in after the fact.

The Street expects sales to grow 1372209.3% in FY27. Consensus EPS is a loss at both ends of that step, so there is no EPS growth rate to take apart.

5 analysts publish an EPS estimate for FY26 and 6 publish revenue. Consensus figures are on the Street's basis and filed figures are GAAP; we label the gap, we do not explain it away.Show coverage by year and over timeHide the coverage chart
Analysts by fiscal year · outlined revenue, filled EPS. Amber marks a panel of fewer than 15.
65
FY26E
67
FY27E
78
FY28E
35
FY29E
55
FY30E
The FY26 panel held 7 analysts when our record of it began on Oct 8, 2026 and holds 5 tonight.

The full consensus, year by year

Consensus as of Nov 16, 2026 · filed figures as reported
Revenue · reporting ccy Bfiled · consensus average · band = low to high
−0.00.10.2historyStreet forecastFY22FY25FY30E

Coverage thins with distance: 6 revenue estimates for FY26, 5 for FY30.

Diluted EPS · reporting ccyfiled · consensus average · band = low to high
−1.89−1.13−0.37historyStreet forecastFY22FY25FY30E

Out-year bands widen as fewer analysts publish: 5 EPS estimates for FY26, 5 for FY30.

Fiscal yearRevenue reporting ccy BYoYEPS reporting ccyYoYEBITDA reporting ccy BNet inc. reporting ccy BShares BAnalysts rev · EPSFwd P/E
FY25Filed · USD0.0—−1.00————as filed—
FY26E0.00.0 to 0.0n/ca−0.61−0.68 to −0.56n/ca−0.1−0.10.096 · 5—
FY27E0.00.0 to 0.0▲1372209.3%−0.67−0.90 to −0.55—−0.1−0.10.096 · 7—
FY28E0.00.0 to 0.0▼86.7%−0.65−0.97 to −0.42—−0.1−0.10.107 · 8—
FY29E0.00.0 to 0.0n/cb−0.70−0.70 to −0.70n/cb−0.1−0.10.093 · 5—
FY30E0.20.2 to 0.2n/cb−0.73−0.73 to −0.73—−0.1−0.10.095 · 5—

Average estimate with low to high beneath. Amber counts mark thin coverage and thin rows carry an amber rule. Shares = consensus net income ÷ consensus EPS, a direction rather than a decimal. The filed row's last column is today's price over the last four reported quarters, the one trailing multiple in that column. a This step crosses the seam: last year is a filed GAAP actual and this year is a consensus estimate, so the two are not prepared on one basis. b More than a third of the analyst panel changed between these two years, so the difference of the two averages measures the panel rather than the forecast.

These are consensus estimates: what analysts expect the business to earn, not where they think the stock trades. Coverage thins and the low to high band widens in the out-years. Context, not advice.

Analysts' price forecasts and grades are not licensed here. This page shows forward consensus estimates only: 5 EPS estimates for FY26, 6 for revenue. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.